Loading…
Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.
Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.
Orladeyo, a capsule taken daily to prevent attacks, is the revenue base; it is sold mainly in the US through specialty pharmacies, with overseas partners selling in some markets. Because patients stay on it for years, revenue recurs, and some proceeds are owed to outside royalty holders from earlier financing.
Moat: narrow (regulatory licence, IP / patents). Approved oral HAE prophylaxis with growing sales, though competing against injectable alternatives.
Headquarters: Durham, North Carolina, US · Founded: 1986 · Employees: 435
Size BioCryst Pharmaceuticals (BCRX) is a United States Health Care company (Biotechnology) with a market value of $1.97B, the 1802nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.69 on 6 Nov 2026.
Performance Over six months the shares fell 10.8%, against +17.1% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 60.3% over the last twelve months (peer median +23.0%); the operating margin is 42.5% (peer median -13.4%).
Valuation It trades at 11.6× forward earnings against a peer median of 55.1× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +118%, so the hurdle is -129 pp: the price already allows for a slowdown.
Short interest Short interest is 10.4% of the free float (15 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $962M | $875M | $451M | $331M | $271M |
| Revenue growth | — | +94% | +36% | +22% | — |
| Gross profit | $941M | $854M | $437M | $325M | $263M |
| EBITDA | n/a | $342M | -$1.30M | -$102M | -$147M |
| Net income | -$360M | $264M | -$88.9M | -$227M | -$247M |
| Free cash flow | n/a | $327M | -$53.1M | -$97.3M | -$163M |
| Capital expenditure | n/a | $2.47M | $1.12M | $2.17M | $1.35M |
| Total debt | $817M | $477M | $841M | $849M | $741M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals BCRX | $1.97B | -11% | +60% | 42% | 11.6× | -10.6% |
| Pharvaris PHVS | $2.41B | +14% | n/a | n/a | n/a | n/a |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | n/a | n/a |
| Intellia Therapeutics NTLA | $1.59B | -19% | +13% | -712% | n/a | n/a |
| Pharming PHARM.AS | $874M | -2% | +2% | 9% | 41.4× | 2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BCRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | +1.5% | 6th lowest of 20 |
| 6-month return | -10.8% | +17.1% | 4th lowest of 20 |
| Distance from 52-week high | -31.5% | -26.1% | 7th lowest of 20 |
| Revenue growth (TTM) | +60.3% | +23.0% | 6th highest of 17 |
| Operating margin | 42.5% | -13.4% | 3rd highest of 16 |
| Forward P/E | 11.6× | 55.1× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -10.6% | 30.5% | least demanding of 5 |
| Growth delivered (Del g) | +117.9% | +20.8% | highest of 5 |
| Hurdle (Req g minus delivered) | -128.5 pp | +16.4 pp | least demanding of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 11.6× | -10.6% | +117.9% |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | n/a | n/a | n/a |
| Alamar Biosciences ALMR | United States | $1.95B | +17% | +195% | -42% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 58.7× | 35.7% | +24.8% |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 51.5× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 119.7× | 25.3% | +3.4% |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 94.1× | 38.7% | +16.8% |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 29.7× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 19.7× | 5.1% | +41.4% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |